Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.64 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.63 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382862 | 0.92 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| SCHEMBL383880 | 0.89 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| Hydrochloric Acid SCHEMBL3380967 | 0.88 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| SCHEMBL382815 | 0.87 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| SCHEMBL383822 | 0.87 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| SCHEMBL1879756 | 0.85 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| SCHEMBL1954088 | 0.85 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| SCHEMBL383403 | 0.85 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| Hydrochloric Acid SCHEMBL384003 | 0.84 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 | |
| Hydrochloric Acid SCHEMBL30829343 | 0.84 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1HDAC8HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | claimed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | claimed |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2015-02-12 | — | — | US | claimed |
| EP-2332909-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2014-10-15 | — | — | EP | claimed |
| US-8530469-B2 | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2013-09-10 | — | — | US | claimed |
| EP-1877379-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2013-01-16 | — | — | EP | claimed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | claimed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | claimed |
| EP-2332909-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | Astex Therapeutics Limited (GB) | 2011-06-15 | — | — | EP | claimed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | claimed |
| EP-2073802-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073804-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073803-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | claimed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | HSP90AA1 2/4885HSP90AB1 3/4885HDAC8 2756/4885 |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC8 278/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | HSP90AA1 105/4885HSP90AB1 49/4885HDAC8 363/4885 |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.